PHGE
BiomX Inc. (PHGE) Risks & Opportunities Analysis (2026)
No material changes this month.
Risks
Current ratio of 0.24 versus better-capitalized peers signals acute liquidity pressure, which can constrain operating flexibility and financing terms over the next 1–5 years.
Interest coverage of -27.3x versus profitable peers indicates earnings are not supporting obligations, increasing refinancing and dilution risk if capital markets tighten.
Days sales outstanding of 360 versus faster-collecting peers implies cash is trapped in receivables, worsening working-capital strain and limiting reinvestment capacity.
Cash conversion cycle of 233 days versus more efficient peers suggests structurally slower cash generation, which can amplify downside in a weak demand or funding environment.
Opportunities
Net debt to EBITDA of -0.12x versus levered peers indicates low net leverage, which can preserve optionality if operating performance stabilizes and funding access remains open.
Debt-to-equity of 0.31 versus more levered peers suggests balance-sheet claims are relatively contained, reducing the probability that creditors dominate future capital allocation.
If receivable collection improves toward peer norms, the large working-capital drag could release cash and partially offset liquidity pressure over the medium term.
Overall Score
PHGE’s forward positioning is constrained primarily by severe liquidity and cash-conversion weakness versus peers, while modest balance-sheet leverage provides only limited offset.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on BiomX Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
